Skip to main content

Broadwood Partners, L.P.'s Form 4 filing

Lineage Cell Therapeutics, Inc.LCTX · filed Feb 8, 2024

Accession no.
0000919574-24-000757
Filed
Feb 8, 2024, 6:58 PM ET
Trade date
Feb 6, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $7.00M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Broadwood Partners, L.P.CIK 0001278386Director, 10% Owner
Bradsher Neal CCIK 0001278388Director, 10% Owner
Broadwood Capital IncCIK 000127838710% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 6, 2024Common SharesPPurchaseAcquired+6,730,770$1.04F2+$7,000,000.841,666,255Direct
Feb 6, 2024Common SharesPPurchaseAcquired0$0.00$041,666,255Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

On February 6, 2024, Broadwood Partners entered into a Stock Purchase Agreement with Lineage Cell Therapeutics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 6,730,770 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in its registered direct offering for a total purchase price of $7,000,000.80, or $1.04 per Common Share.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)